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Newborn screening of duchenne 
muscular dystrophy specifically 
targeting deletions amenable 
to exon‑skipping therapy
Pablo Beckers1, Jean‑Hubert Caberg2, Vinciane Dideberg2, Tamara Dangouloff3, 
Johan T. den Dunnen4, Vincent Bours5, Laurent Servais3,6 & François Boemer1*
Duchenne Muscular Dystrophy (DMD) is a lethal progressive muscle‑wasting disease. New treatment 
strategies relying on DMD gene exon‑skipping therapy have recently been approved and about 
30% of patients could be amenable to exon 51, 53 or 45 skipping. We evaluated the spectrum of 
deletions reported in DMD registries, and designed a method to screen newborns and identify DMD 
deletions amenable to exon 51, 53 and 45 skipping. We developed a multiplex qPCR assay identifying 
hemi(homo)‑zygotic deletions of the flanking exons of these therapeutic targets in DMD exons (i.e. 
exons 44, 46, 50, 52 and 54). We conducted an evaluation of our new method in 51 male patients with 
a DMD phenotype, 50 female carriers of a DMD deletion and 19 controls. Studies were performed on 
dried blood spots with patient’s consent. We analyzed qPCR amplification curves of controls, carriers, 
and DMD patients to discern the presence or the absence of the target exons. Analysis of the exons 
flanking the exon‑skipping targets permitted the identification of patients that could benefit from 
exon‑skipping. All samples were correctly genotyped, with either presence or absence of amplification 
of the target exon. This proof‑of‑concept study demonstrates that this new assay is a highly sensitive 
method to identify DMD patients carrying deletions that are rescuable by exon‑skipping treatment. 
The method is easily scalable to population‑based screening. This targeted screening approach could 
address the new management paradigm in DMD, and could help to optimize the beneficial therapeutic 
effect of DMD therapies by permitting pre‑symptomatic care.
Abbreviations
DMD  Duchenne muscular dystrophy
BMD  Becker muscular dystrophy
qPCR  Quantitative polymerase chain reaction
MLPA  Multiplex ligation-dependent probe amplification
Duchenne Muscular Dystrophy (DMD) is the most common and severe form of muscular dystrophy, marked by 
progressive muscle degeneration. DMD is caused by variants—mostly out-of-frame—in the DMD gene, which 
encodes for the protein  dystrophin1. Dystrophin interacts with other proteins to maintain the integrity and 
structure of musculoskeletal fibers in skeletal and cardiac (i.e. striated) muscle. In DMD patients, pathogenic 
variants of the DMD gene lead to a complete lack of dystrophin production. Involvement of striated muscle 
begins in early childhood, generally before the age of three years and is predominantly observed in males. Becker 
Muscular Dystrophy (BMD) also involves the DMD gene, and is characterized by residual dystrophin production, 
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so that BMD patients present later with a milder clinical  phenotype2. Nearly all patients with BMD harbour an 
in-frame pathogenic variant/mutation.
Deletions of one or more exons of the DMD gene account for approximately 60–70% of pathogenic variants 
in patients with DMD and  BMD3. Recently, novel therapeutic approaches to DMD involving exon skipping 
have been developed. These RNA-level therapies aim to skip the flanking exon of an out-of-frame mutation to 
transform it to an in-frame mutation, in order to induce the synthesis of a truncated and partially functional 
dystrophin  protein4,5. Eteplirsen (Exondys) and golodirsen (Vyondys 53) were approved by the Food and Drug 
Administration (FDA) for the treatment of DMD in patients who carry a confirmed mutation that is amenable to 
exon 51 and exon 53 skipping,  respectively6,7. Several other similar approaches, such as, suvodirsen, viltolarsen, 
casimersen, or rAAV-U7snRNA-E538, targeting exons 51, 53 or 45, are or have been under evaluation to expand 
the spectrum of treatable DMD patients.
Apart from exon-skipping approaches, several gene therapy strategies are also under investigation. Ataluren 
(PTC124), an approved drug in Europe, enables ribosomal readthrough of premature nonsense mutations to 
produce full-length, functional dystrophin and has shown promising results in several  studies2,9. Gene therapy 
using microdystrophin has proven efficacy in different canine models of  DMD10,11. Three phase I/II clinical trials 
are also ongoing to assess the safety of AAV-microdystrophin intravenous injection (ClinicalTrials identifier: 
NCT03368742, NCT03769116, NCT03362502). Many other downstream therapeutic alternatives are currently 
under investigation, such as, upregulation of utrophin, using GALGT2 gene  therapy12,  idebenone13,  givinostat14, 
or  edasalonexent15.
Considering the current advances in DMD treatment, newborn screening (NBS) programs for DMD are 
increasingly being  considered16–18. Indeed, there is increasing awareness that DMD patients amenable to exon-
skipping should be treated as early as possible (i.e. from birth) in order to maximize the beneficial therapeutic 
 effect16,17. In keeping with this, a study of the safety and efficacy of eteplirsen is ongoing in children as young as 
six months (ClinicalTrials identifier: NCT03218995).
To date, technical aspects of population-based screening for DMD have been evaluated in pilot studies. 
These assessments systematically considered the quantification of creatine kinase (CK), or its muscular isoform 
(CKMM), on dried blood spots (DBS) as a primary marker of  DMD19–24. CK is a marker of the disease process 
and does not directly reflect the genetic defect. Accordingly, both false negatives and false positives occur using 
either CK or CKMM assays as a first-line test. Another important consideration is that not all DMD patients 
would benefit from early treatment since current approved therapies only target specific defects of DMD gene. 
In addition, gene-transfer by adeno-associated virus that could cover all phenotype is not currently evaluated at 
birth, since the weight-limited dose that can be administered in a newborn would be severely diluted by growth, 
with no possibility to re-administer later in life.
Consequently, we have designed an assay for the early identification of DMD molecular defects that could be 
amenable to exon skipping therapies targeting exons 51, 53 and 45. This approach involves a multiplex quantita-
tive polymerase chain reaction (qPCR) assay to identify hemi(homo)–zygotic deletions of exon 44, 46, 50, 52 
and 54 of DMD gene (i.e. the flanking exons of exon-45, exon-51 and exon-53-skipping targets) on dried blood 
spots. We set out to identify 100% of treatable DMD patients that could benefit from early treatment. The method 
also leads to the identification of a small subgroup of DMD that cannot be treated by exon skipping; however, 
in those patients an early diagnosis is provided.
Results
Database review. Our approach was to identify patients amenable to exon-skipping therapy by screening 
for individuals with hemi(homo)-zygotic deletions of the flanking exons of exon-skipping targets. Identification 
of a deletion of any of these flanking exons does not, however, invariably involve a genotype that could benefit 
from these treatments. For example, a deletion of flanking exon 46 may indicate a deletion of exons 45–47, or a 
deletion of exons 46–49. The in-frame deletion of exons 45–47 would not benefit from exon-45 skipping, while 
the out-of-frame deletion of exons 46–49 can be rescued by skipping of exon-45 (Fig. 1A).
To determine the efficiency of our approach, we assessed the percentage of DMD patients reported in the 
LOVD-DMD registry that would be identified by our assay and would be rescuable by either exon-51, exon-53 
or exon-45 skipping therapy (Fig. 1B). This analysis also shows that assaying the flanking exons is an effective 
approach to identify many patients that could benefit from these therapies (Table 1).
qPCR results. We analyzed 120 samples with known genotypes. Deletion of any of the five target exons 
(exons 44, 46, 50, 52 and 54) of the DMD gene was characterized by the absence of amplification of the corre-
sponding target. As shown in Table 2, the assay correctly identified all subjects, with either presence or absence 
of amplification of the target exon. To corroborate the absence of amplification, for each exon, an NFR below 0.2 
was found as being discriminant between the deleted group and the carrier and control groups.
Within the “deleted group” (n = 51), there were 10 different deletion patterns seen: a deletion overlapping 
exon 44 (n = 4 patients), a deletion overlapping exon 46 to 54 (n = 5), a deletion overlapping exon 46 to 52 (n = 2), 
a deletion overlapping exon 46 to 50 (n = 7), a deletion overlapping exon 46 (n = 7), a deletion overlapping exon 
50 to 54 (n = 3), a deletion overlapping exon 50 (n = 3), a deletion overlapping exon 52 to 54 (n = 2), a deletion 
overlapping exon 52 (n = 1), and patients with a deletion not overlapping any target exon (n = 17).
The 34 DMD patients of the “deleted group” with a deletion overlapping at least one of the five target exons 
were correctly characterized by an absence of fluorescence of the corresponding probes. The other 17 male 
patients of the “deleted group”, with a deletion of a DMD exon not targeted by our assay, presented a clear 
amplified profile of all target exons. All subjects of the female “carrier group” and the “control group” also were 
characterized by a normal significant fluorescent signal of each probe. Our assay did not discriminate between 
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carrier females and controls. The amplification profile of each target exon is summarized in Fig. 2. The results 
demonstrate that the technique achieved 100% sensibility and 100% specificity in the population studied.
Discussion
We show the feasibility and reliability of a simple test to detect newborns with DMD that would be eligible for 
exon skipping therapy. Our study is a proof-of-concept approach to NBS for DMD using a qPCR method. We 
set up a high-throughput assay to target deletions that are amenable to exon-51, exon-53 or exon-45 skipping 
treatments (i.e. screening for deletion of exons 44, 46, 50, 52 and 54 of the DMD gene). We analyzed 51 DMD 
patients, 50 female DMD gene deletion carriers and 19 healthy individuals without any deletion of the DMD 
gene. Each of the 120 subjects was correctly categorized by the assay with either the presence or absence of 
Figure 1.  (A) Reading frame from exons 41 to 53 of DMD gene (upper frame). Example of the in-frame 
deletion of exons 45–47, which cannot benefit from exon-45 skipping (central frame). Example of the out-of-
frame deletion of exons 46–49, which is amenable to exon-45 skipping (lower frame). (B) Number of patients 
with a large deletion (≥ 1 exon) covering at least one flanked exon reported in LOVD-DMD database. Deletions 
involving 35 or more patients are shown. Blue-bars point the deletions rescuable to either single exon-51, exon-
53 or exon-45 skipping, red-bars correspond to deletion not rescuable by the aforementioned therapies.
Table 1.  Number of patients reported in LOVD-DMD database, and proportion of these patients that would 
be rescuable by either exon-51, exon-53 or exon-45 skipping. a LOVD-DMD database accessed on April  20th 
2020. b The numbers of patients with a deletion of at least one flanking exon corresponds to the number of 
DMD patients reported in LOVD-DMD database that would be identified by our assay. c Of the 9532 DMD 
patients identified by our assay, 5144 would benefit from either exon 51, 53 or 45 skipping.
Number of patients
Number of patients that would benefit from either 
exon 45, 51 or 53 skipping (%)
Entries reported in  databasea 26,078
Patients with a deletion of DMD gene 16,414
Patients with a deletion covering at least one flanking 
exon 9532
b 5144 (54.0)c
Patients with a deletion overlapping at least exon 44 1075 511 (47.5)
Patients with a deletion overlapping at least exon 46 5357 1016 (19.0)
Patients with a deletion overlapping at least exon 50 5494 2034 (37.0)
Patients with a deletion overlapping at least exon 52 3375 1583 (46.9)
Patients with a deletion overlapping at least exon 54 1386 0 (0.0)
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amplification of the target exon corresponding to their known genotype. Should a very rare variant affect the 
specificity of our primers and probes, we expect scoring a false positive result due to absence of amplification.
DMD is devastating muscle disease with an early onset. However, due to a 1.3–2.5 year delay in clinical 
diagnosis after the appearance of first symptoms, the mean age at diagnosis of DMD patients is 4.4 years25–27. 
Since early treatment is  recommended16–18, reducing the delay before diagnosis might be aided via the inclusion 
of DMD in newborn screening performed under existing public health screening protocols. To the best of our 
knowledge, only exon-skipping is being studied to date in children as young as six months of age (ClinicalTrials 
identifier: NCT03218995). Pre-treating patients before gene therapy using an exon-skipping approach could 
potentiate the effect of gene therapy. Such pre-treatment would allow the use of lower-and therefore safer-doses 
of vector to bring about a higher level of dystrophin expression in the long  term28,29.
Table 2.  Amplification results of the different subject groups: “deleted group”, “carrier group” and “control 
group”. a = male patients with a DMD deletion not overlapping any of the 5 target exons. b = female subjects 
carrying a DMD deletion overlapping at least one of the 5 target exons. c = female subjects carrying a DMD 
deletion not overlapping any of the 5 target exons. d = Deleted exons were identified through MLPA. Intronic 
breakpoints have not been sequenced; genotypes are reported according to the LOVD-DMD database. *Results 
show if the target exon is deleted (Del) or amplified (Ampli). N/A Not Applicable.
Subject group
Target DMD exon
Genotyped Number of patientsExon 44 Exon 46 Exon 50 Exon 52 Exon 54
Deleted group Del* Ampli* Ampli Ampli Ampli del_13-44
n = 34 (total)
Deleted group Del Ampli Ampli Ampli Ampli del_44
Deleted group Del Ampli Ampli Ampli Ampli del_20-44
Deleted group Del Ampli Ampli Ampli Ampli del_20-44
Deleted group Ampli Del Del Del Del del_46-55
Deleted group Ampli Del Del Del Del del_45-55
Deleted group Ampli Del Del Del Del del_45-55
Deleted group Ampli Del Del Del Del del_45-55
Deleted group Ampli Del Del Del Del del_45-55
Deleted group Ampli Del Del Del Ampli del_46-53
Deleted group Ampli Del Del Del Ampli del 46–52
Deleted group Ampli Del Del Ampli Ampli del_45-50
Deleted group Ampli Del Del Ampli Ampli del_45-50
Deleted group Ampli Del Del Ampli Ampli del_45-50
Deleted group Ampli Del Del Ampli Ampli del_45-50
Deleted group Ampli Del Del Ampli Ampli del_45-50
Deleted group Ampli Del Del Ampli Ampli del_45-50
Deleted group Ampli Del Del Ampli Ampli del_45-50
Deleted group Ampli Del Ampli Ampli Ampli del_45-47
Deleted group Ampli Del Ampli Ampli Ampli del_45-47
Deleted group Ampli Del Ampli Ampli Ampli del_45-47
Deleted group Ampli Del Ampli Ampli Ampli del_45-46
Deleted group Ampli Del Ampli Ampli Ampli del_46-48
Deleted group Ampli Del Ampli Ampli Ampli del_45-48
Deleted group Ampli Del Ampli Ampli Ampli del_45-48
Deleted group Ampli Ampli Del Del Del del_48-55
Deleted group Ampli Ampli Del Del Del del_49-54
Deleted group Ampli Ampli Del Del Del del_49-54
Deleted group Ampli Ampli Del Ampli Ampli del_50
Deleted group Ampli Ampli Del Ampli Ampli del_50
Deleted group Ampli Ampli Del Ampli Ampli del_50
Deleted group Ampli Ampli Ampli Del Del del_51-55
Deleted group Ampli Ampli Ampli Del Del del_51-64
Deleted group Ampli Ampli Ampli Del Ampli del_52
Deleted group Ampli Ampli Ampli Ampli Ampli N/Aa n = 17
Carrier group Ampli Ampli Ampli Ampli Ampli N/Ab n = 32
Carrier group Ampli Ampli Ampli Ampli Ampli N/Ac n = 18
Control group Ampli Ampli Ampli Ampli Ampli Normal n = 19
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The availability of personalized treatments represents a paradigm shift in the management of the subset of 
DMD patients that are amenable to their use, particularly as treatment can now be initiated pre-symptomatically. 
Deployment of our test raises some challenges as it addresses a subset of patients in which the use of an exon 
skipping therapy is possible. For those patients and their families, the benefit of early diagnosis of DMD is clear. 
For the large proportion of patients that are currently not suitable for these therapies, the ongoing development 
of gene therapy offers hope, albeit that significant clinical hurdles need to be overcome. For these patients, early 
diagnosis is still relevant to allow for the timely introduction of physiotherapy and corticosteroids. As part of 
evolving improvements in the treatment of DMD, we believe that our approach represents an effective and 
practical optimization of diagnosis. As therapeutic options expand, this test could also evolve as part of a more 
comprehensive DMD testing strategy when combined with other techniques.
Initiatives have previously been undertaken in various countries to explore the feasibility and efficacy of 
NBS for  DMD19–23. Those studies, relying either on CK or CKMM quantitation, achieved modest sensitivity 
and specificity. The Wales DMD newborn screening program, for example, has carried out CK quantitation as 
a first-tier test on more than 340,000 neonates. The CK assay has shown a sensitivity of 81.6% with a positive 
predictive value of 38.6%20. More recently, a CKMM assay was evaluated in two independent populations in a 
limited number of  newborns23. That study reported one false negative result on a premature infant. Authors also 
showed that both the gestational age and the age of the newborn at time of sampling affecting CKMM levels. 
This can become an issue when screening large populations with significant subgroups of preterm neonates, 
and could greatly impact the number of second-tier molecular tests required to confirm DMD diagnosis. Com-
paratively, while restricted to a small number of samples, our assay presented a sensitivity of 100%. Experience 
shows that qPCR assays dedicated to the NBS of spinal muscular atrophy (i.e. a technically similar assay) have 
very high sensitivities and  specificities30–32. We suggest that there is a reasonable expectation that the DMD assay 
we describe could perform similarly in larger cohorts.
Figure 2.  Amplification curves and scattered endpoint fluorescence of control group and carrier group, and 
DMD patients with a deletion of at least one target exon (deleted group). (A) Amplification curves of a patient 
without deletion of any target exons. (B) Amplification curves of a patient with a deletion of exons 50 to 54. (C) 
Normalized Fluorescence Ratio (NFR) of control and carrier group versus deleted group (i.e. DMD patients 
with a deletion overlapping at least one of the five target exons).
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This study acts as a feasibility study for designing a subsequent wider NBS project for DMD. Technically, 
since our real-time PCR reader is equipped with five fluorescence channels, a two-step validation protocol is 
necessary. Results showing an amplification of either one or more exons are acceptable, as any amplified exon can 
act as a reference sequence. Samples showing no amplification for any of the five exons (i.e. any DMD deletion 
covering exons 44 to 54) would be re-run in a 2-plex qPCR reaction, combining each individual exon with the 
RPP30 reference gene to confirm the deletion. In the context of neonatal screening, positive results would be 
confirmed on a fresh-EDTA sample using the MLPA assay, as the test is already commercially available. MLPA 
testing, combined with an analysis of the RNA transcript, is also mandatory to establish precisely the individual 
genotype, confirming whether a patient is eligible for exon-skipping therapy.
Regarding the experimental conditions, the qPCR assay we describe is highly practical, robust and easily 
scalable to population-based screening. It is also not economically burdensome (less than 5 euros per sample), 
considering that the DNA is already extracted for NBS of other molecular genetic diseases. These other targets 
include spinal muscular  atrophy33,34 another devastating genetic condition without circulating diagnostic bio-
markers for which innovative medications have dramatically changed the prognosis when administered early, 
and that has prompted several NBS  programs30–32. In the future, societal and medical cost-effectiveness evalu-
ations could be carried out on large population to compare the “qPCR/MLPA” protocol we describe with the 
two-tier “CKMM DMD genotyping” strategy proposed by Mendell et al.24. In the context of developing an NBS 
algorithm for DMD, our qPCR assay could also be considered as a second-line fast-track procedure to rapidly 
identify whether CKMM positive samples would be eligible for exon-skipping therapies.
Although DMD is expected to affect only male patients, and the costs of processing the sorting of samples 
by gender greatly exceed the low costs of analysis, we envisage performing screening on both male and female 
neonates. We could thereby identify the very rare cases of DMD in women with co-existing Turner  syndrome35. 
On the other hand, a few cases of female carriers expressing a DMD phenotype have been described in situation 
of X-chromosome inactivation (XCI)  skewing36. Our assay is not intended to identify carriers of a DMD deletion, 
and females with a DMD phenotype related to non-random patterns of XCI would be missed.
DMD patients eligible for either exon-51, exon-53 or exon-45 skipping treatments account for approximately 
30% of DMD  cases37. With an incidence evaluated at about of 1/5,000 males in the general  population38, approxi-
mately 1/15,000 males could be identified using our approach, which is far above other commonly accepted 
disorders in NBS programs. Our multiplex PCR is not intended to detect all deletions in the DMD gene nor can 
it identify duplications or point mutations. A negative result on the current assay does therefore not definitively 
rule out a diagnosis of DMD, since about 70% of DMD patients are not eligible for either exon-51, exon-53, 
or exon-45 skipping therapies and would not be identified by our assay. Nevertheless, the spectrum of DMD 
genotypes potentially rescuable by single or double antisense-mediated exon skipping is constantly growing. The 
actual applicability of exon skipping approach, assessing which exon(s) should be skipped to restore the open 
reading frame in DMD gene, could theoretically benefit 83% of patients with  DMD37. Should any future DMD 
therapies targeting other exons or specific variants be developed, our method could be easily scaled-up to target 
DMD exons other than 51, 53 and 45, thereby extending its applicability to a wider panel of DMD genotypes. 
qPCR technology has some limitations and cannot identify the entire panel of variants described in the DMD 
gene. Next-generation sequencing (NGS) represents the ultimate approach to screen newborns for DMD. Not-
withstanding, NGS is currently too expensive to be used for full population screening for the foreseeable future.
Our methodology could raise some ethical concerns regarding DMD patients who would be left out by our 
assay. Our approach is, however, not the first initiative of NBS prompted by innovative therapies that misses 
some cases affected by a particular disease. Indeed, NBS for spinal muscular atrophy is nowadays largely accepted 
amongst pediatricians, families and advocacy groups, although screening assays specifically focus only on the 
identification of homozygotic deletions of the SMN1 gene and miss SMN1 heterozygotic and SMN2 deletions. 
Screening for spinal muscular atrophy using this method was added to the Recommended Uniform Screening 
Panel (RUSP), the official list of disorders which US public health departments use to screen newborns, despite 
the availability of only one approved treatment. Type 0 spinal muscular atrophy patients were, therefore, identi-
fied by screening, but could not benefit from any specific treatment available at that time.
The DMD population diagnosed at birth with our test accounts for approximately 9532/26078 (36.5%) in 
the LOVD database. Overall, 5144/26078 (19.7%) could be offered gene therapy. The remaining 4388/26078 
(16.8%) that are diagnosed with exon deletions but are not amenable to current therapy, also have significant 
potential benefits stemming from early diagnosis. In this latter group, physiotherapy and steroids could be 
implemented years earlier than the current situation in which they are simply waiting for DMD to manifest 
clinically. Currently, physiotherapy and corticosteroids are typically initiated about the age of 4 years, even in 
patients diagnosed earlier. At that time, more than half of patients will have been  diagnosed39. NBS of all DMD 
patients could reduce diagnosis journey and anticipate familial recurrence, but since the age at diagnosis is not 
the main driving factor for initiating disease-specific treatment like steroids, there is no more rationale to screen 
today all DMD patients than any recessive rare disorders, which explain why DMD is not usually part of NBS 
programs. The approval of new disease-modifying treatment brings a new insight for a subset of patients with a 
deletion amenable to treatment. The introduction of our novel screening test would thus not negatively impact 
the current management of DMD cases, while adding an easy, non-expensive, and efficient way to detect 100% 
of the patients that are eligible for gene therapy.
One of the limitations of this approach could be the development of non-mutation specific treatments such 
as microdystrophin. Nevertheless, gene therapy as a one-shot injection will probably not be applicable before 
the age of two years, and is currently in trials after the age of 4. The risk of a dilution effect through growth could 
limit the treatment of newborns. In this context, the pre-treatment of eligible exon skipping therapy patients 
from birth until microdystrophin injection could help to potentiate gene therapy  treatment40.
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Conclusion
In conclusion, we provide proof-of-concept of a test that can potentially detect DMD patients at birth that are 
eligible for currently approved exon skipping 51, 53 and 45 therapies. The development of this assay was driven 
by the approval of exon-skipping drugs in DMD management. Our test addresses a significant paradigm shift 
in NBS, by identifying newborns amenable to a specific available treatment, rather than detecting all newborns 
with a particular disease. This method meets a specific current -and possibly transitory- need in DMD care, 
focused on the identification of patients that could benefit from exon-skipping therapies. Early identification 
of DMD holds promise for preserving functional performance in affected children via the initiation of treat-
ment at a young age. Should the current assay’s performance be further validated in larger studies, it could act 
as a means to improve DMD patient identification and management in the clinical setting for countries where 
exon-skipping drugs are available.
Materials and methods
DMD registry analysis. We reviewed the Leiden Open Variation Database for the DMD gene (LOVD-
DMD), that currently contains more than 26,000 patient  entries41. We evaluated the spectrum of reported dele-
tions to provide a theoretical rationale for the development of an assay identifying deletions that could benefit 
from either exon-51, exon-53 or exon-45 skipping therapies.
Subjects. Blood from DMD and control samples were collected as dried blood spots (DBS). DMD gene 
profile of all patients was performed using Multiplex Ligation-Dependent Probe Amplification (MLPA) assay in 
the course of diagnostic workup.
In total, 120 samples were collected and were classified into three different subgroups:
The “deleted group” consisted of 51 male patients with a clinical DMD phenotype. Amongst them, 34 had a 
confirmed deletion of one or more DMD exons amenable to exon-skipping targeted therapies (i.e. exons 44, 46, 
50, 52 or 54). The other 17 male patients carried a deletion of another DMD exon.
The “carrier group” included 50 females with one deleted DMD allele, of whom 32 carried a deletion that 
overlapped at least one of the target exons 44, 46, 50, 52 or 54, while 18 had a deletion of any other DMD exon.
The “control group” consisted of 19 normal individuals with no DMD deletion/duplication or point mutations.
qPCR Technical design. The DMD genotyping assay was designed and validated to detect hemi-(homo)-
zygotic deletions of DMD exons 44, 46, 50, 52 and 54. The protocol uses a multiplex quantitative polymerase 
chain reaction (qPCR) assay.
DNA was extracted from one 3.1-mm dried blood spot according to the protocol described previously  in33. 
Isolated DNA was not quantitated, and 1 µL of freshly extracted DNA was mixed with 5 × Takyon master mix 
(Eurogentec), primers and probes in a total volume of 25 µL. The sequences and concentrations of primers 
and probes are shown in Table 3. Primers and probes have been designed to have the fewest possible described 
polymorphisms (Supplemental Table 1).
Table 3.  qPCR primers and probes used to amplify and identify DMD Exons 44, 46, 50, 52 and 54.
Target Sequence Concentration (nmol/L)
DMD exon 44
Forward primer 5′- TAC CTG CAG GCG ATT TGA C -3’ 300
Reverse primer 5′- CAC CCT TCA GAA CCT GAT CTT T -3’ 300
Probe 5′- FAM—AAA TTC CTG AGA ATT GGG AAC ATG—BHQ -3’ 130
DMD exon 46
Forward primer 5′- TTT ATG GTT GGA GGA AGC AGA -3’ 300
Reverse primer 5′- AAT GGG CAG AAA ACC AAT GA -3’ 300
Probe 5′- YakimaYellow—AAC CTG GAA AAG AGC AGC AAC T—BHQ -3’ 90
DMD exon 50
Forward primer 5′- CTG AGT GGA AGG CGG TAA AC -3’ 300
Reverse primer 5′- TCT CAC CCA GTC ATC ACT TCA -3’ 300
Probe 5′- ROX—ACT TCA AGA GCT GAG GGC AAAG—BHQ -3’ 80
DMD exon 52
Forward primer 5′- AAT ACA CAA CGC TGA AGA ACC C -3’ 300
Reverse primer 5′- TTG TGT GTC CCA TGC TTG TT -3’ 300
Probe 5′- Atto 647 N—CGC TGC CCA AAA TTT GAA AAA—BHQ -3’ 150
DMD exon 54
Forward primer 5′- TCT ATA GCA GTT GGC CAA AGA C -3’ 300
Reverse primer 5′- TCA TGG TCC ATC CAG TTT CA -3’ 300
Probe 5′- Atto 700—AAT ATC AAT GCC TCT TGG AGA AGC—BHQ -3’ 180
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Assays were run on a CFX96 Real-Time PCR System (Biorad) under the following conditions: 95 °C for 5 min, 
followed by 40 cycles of 95 °C for 30 s and 61 °C for 75 s.
Interpretation of findings. To normalize amplification results and to facilitate the interpretation, a nor-
malized fluorescence ratio (NFR) was calculated dividing the endpoint fluorescence of each sample by the 
median endpoint fluorescence of the corresponding exon of all samples of the same run.
Ethics. The study was approved by the local ethics committees and patients or guardians provided written 
informed consent (2019/278 and CEH 84/19). All experiments were performed in accordance with relevant 
guidelines and regulations.
Ethics approval and consent to participate. The study was approved by the local ethics committees 
and patients or guardians provided written informed consent (2019/278 and CEH 84/19). All experiments were 
performed in accordance with relevant guidelines and regulations. Hôpital Universitaire des Enfants Reine Fabi-
ola (ULB): Members: Mr F Devaux, Dr J Groswasser, Mrs G Hendrijckx, Mrs K Van Aerschot, Mrs N Andersson, 
Mr P Lemaire, Dr H Demanet, Dr A Ferster, Dr C Fonteyne, Dr C De Laet, Dr D Biarent, Dr V Vlieghe, Dr P 
Simoni, Mrs L Lambotte. CHU Liege: Members: Dr V Seutin, Dr J Demonty, Dr G Daenen, R Agirman, Dr E 
Baudoux, Dr A Blavier, Dr F Caeymax, Mme MN Englebert, Dr P Firket, Mme I Hemans, Dr M Lamy, Dr M 
Lejeune, Mr P Lissens, Mme P Modanese, Dr AS Parent, Dr M Radermecker, Dr R Radermecker, Mme I Roland, 
Dr I Ruten, Mme C Thirion.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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